<i>In Vivo</i> Efficacy of Tesevatinib in <i>EGFR</i> -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
Sani H. Kizilbash(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic in Arizona)
Cited by 13
Related Papers
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
|Journal of Clinical Oncology|2008|275
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
|Molecular Cancer Therapeutics|2007|203